Marksans Pharma Q2 FY27: Revenue surges 30.5% to ₹940 Cr, EBITDA up 48.3%
Marksans Pharma reported a record Q2 FY27 with revenue up 30.5% to ₹940 crore and EBITDA up 48.3% to ₹214 crore. Growth was strong across North America, Europe, UK, and Australia. The company aims to reach ₹4,000 crore revenue next year and is evaluating capacity expansion and M&A opportunities.
The announcement details a record quarterly performance with strong financial metrics, including significant revenue and profit growth. It also outlines clear growth strategies and expansion plans, which are material to investors.
The company reported record quarterly performance with significant year-on-year growth in revenue and EBITDA, alongside improved margins. Management expressed confidence in future growth prospects across various geographies and strategic initiatives.
Marksans Pharma Limited announced its Q2 FY27 financial results, reporting a record quarterly performance with revenue from operations reaching ₹940 crore, a significant year-on-year growth of 30.5%. The company also saw a substantial improvement in profitability, with EBITDA increasing by 48.3% to ₹214 crore, and EBITDA margin expanding by 274 basis points to 22.8%.
The growth was driven by strong momentum across Europe, the UK, and continued growth in North America, with Australia and New Zealand also contributing positively. The underlying business, excluding acquisitions, delivered approximately 25% growth.
Geographically, North America contributed ₹421 crore (44.8% of revenue), while the UK and Europe together contributed ₹405 crore (43%). Australia and New Zealand added ₹101 crore (10.7%). The company's performance reflects the strength of its geographically diversified business model.
For the first half of FY27, total income stood at ₹1,825 crore, with revenue from operations at ₹1,781 crore, an increase of 32.9%. EBITDA grew by 74.7% to ₹427 crore, and profit after tax increased by 92.5% to ₹303 crore. The company also highlighted strong cash generation, with INR322 crore from operations, and a net cash position of ₹1,095 crore as of September end.
Looking ahead, Marksans Pharma plans to deepen its presence in existing markets, scale its European platform, expand its product portfolio, and selectively enter new markets. The company is also considering capacity expansion in India through adding blocks to existing facilities or acquiring a new plant, with dialogues underway with two companies.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.